Development of multispecific assemblies of Nanofitins® with anti-tumor activities @ PEGS Europe 2021

Ms. Perrine Jacquot, Ph.D. student working at Affilogic and at the Western Cancer Institute (Institut de Cancérologie de l’Ouest, Saint-Herblain, France) presented her latest results in November in Barcelona during PEGS Europe 2021. Read more

Nanofitins targeting heat shock protein 110: an innovative immunotherapeutic modality in cancer

Affilogic recently published with some partners an article on anti-HSP110 Nanofitins in cancer immunotherapy. Read more

This work was performed in collaboration with INSERM (UMR1231), University of Bourgogne Franche-Comté, Anticancer Center Georges François Leclerc and the company Inovotion.

Affilogic to receive public funding for a new production unit as winner of the French industrial relocation plan

Affilogic is one of the first 31 winners of the industrial relocation plan recently unveiled by the Minister of the Economy, Bruno Le Maire. Within three years, it wants to create a production unit for the Nanofitins, synthetic proteins (…), which are designed to attach themselves to a chosen biological target to purify it, detect it, or block its action. These molecules are used in particular to inhibit pathological mechanisms. “The major pathologies targeted include Crohn’s disease, pancreatic cancer, brain and ophthalmic diseases,” explains Olivier Kitten, the CEO. “(…) Today, we want to create a 1,500 m² unit in the Nantes region to multiply our production capacity by a factor of 100. » With this €5 million investment, Affilogic is set to double its workforce (currently 25 people) in Nantes over three years.